Concepts (242)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Heart Failure | 27 | 2025 | 298 | 4.130 |
Why?
|
| Heart Valve Prosthesis Implantation | 6 | 2024 | 26 | 2.800 |
Why?
|
| Cardiovascular Diseases | 14 | 2025 | 729 | 2.450 |
Why?
|
| Heart Valve Prosthesis | 5 | 2024 | 45 | 2.090 |
Why?
|
| Mitral Valve | 4 | 2024 | 37 | 1.800 |
Why?
|
| Ventricular Function, Left | 9 | 2025 | 111 | 1.760 |
Why?
|
| Stroke Volume | 15 | 2021 | 122 | 1.740 |
Why?
|
| Thrombosis | 3 | 2024 | 81 | 1.560 |
Why?
|
| Ventricular Remodeling | 4 | 2023 | 58 | 1.520 |
Why?
|
| Myocardial Infarction | 4 | 2023 | 242 | 1.460 |
Why?
|
| Mitral Valve Insufficiency | 3 | 2021 | 22 | 1.440 |
Why?
|
| Registries | 16 | 2025 | 431 | 1.360 |
Why?
|
| Aortic Valve Stenosis | 5 | 2023 | 33 | 1.340 |
Why?
|
| Postoperative Complications | 2 | 2024 | 253 | 1.330 |
Why?
|
| Singapore | 17 | 2025 | 32 | 1.230 |
Why?
|
| Coronary Artery Disease | 4 | 2025 | 164 | 1.180 |
Why?
|
| Prosthesis Design | 3 | 2024 | 48 | 1.100 |
Why?
|
| Humans | 69 | 2025 | 42163 | 0.940 |
Why?
|
| Aged | 35 | 2025 | 7982 | 0.940 |
Why?
|
| Middle Aged | 43 | 2025 | 11819 | 0.930 |
Why?
|
| Exercise Tolerance | 2 | 2015 | 22 | 0.920 |
Why?
|
| Bioprosthesis | 1 | 2024 | 6 | 0.910 |
Why?
|
| Hospitalization | 9 | 2025 | 482 | 0.890 |
Why?
|
| Quality of Life | 8 | 2021 | 599 | 0.870 |
Why?
|
| Diabetes Mellitus, Type 2 | 3 | 2021 | 744 | 0.840 |
Why?
|
| Risk Factors | 19 | 2025 | 3942 | 0.810 |
Why?
|
| Treatment Outcome | 12 | 2024 | 1586 | 0.810 |
Why?
|
| Risk Assessment | 9 | 2025 | 845 | 0.810 |
Why?
|
| Male | 50 | 2025 | 22779 | 0.800 |
Why?
|
| Prospective Studies | 17 | 2021 | 1574 | 0.800 |
Why?
|
| Aortic Valve | 5 | 2023 | 38 | 0.800 |
Why?
|
| Asia | 12 | 2025 | 99 | 0.760 |
Why?
|
| Exercise Test | 3 | 2018 | 75 | 0.720 |
Why?
|
| Stroke | 2 | 2023 | 348 | 0.690 |
Why?
|
| Myocardium | 2 | 2023 | 251 | 0.690 |
Why?
|
| Air Pollutants | 2 | 2019 | 127 | 0.680 |
Why?
|
| Female | 44 | 2025 | 24018 | 0.670 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2023 | 188 | 0.670 |
Why?
|
| Coronary Vessels | 2 | 2018 | 92 | 0.660 |
Why?
|
| Jugular Veins | 1 | 2020 | 7 | 0.660 |
Why?
|
| Catheterization, Central Venous | 1 | 2020 | 9 | 0.660 |
Why?
|
| Randomized Controlled Trials as Topic | 4 | 2025 | 358 | 0.640 |
Why?
|
| Health Knowledge, Attitudes, Practice | 2 | 2025 | 959 | 0.640 |
Why?
|
| Macrophages | 3 | 2023 | 515 | 0.620 |
Why?
|
| Ventricular Dysfunction, Left | 1 | 2020 | 96 | 0.600 |
Why?
|
| Calcinosis | 1 | 2019 | 61 | 0.600 |
Why?
|
| Particulate Matter | 1 | 2019 | 80 | 0.570 |
Why?
|
| Immunity, Innate | 1 | 2019 | 168 | 0.560 |
Why?
|
| Time Factors | 8 | 2024 | 1848 | 0.530 |
Why?
|
| Electrocardiography | 5 | 2021 | 184 | 0.520 |
Why?
|
| Financial Management | 1 | 2016 | 6 | 0.510 |
Why?
|
| Long QT Syndrome | 1 | 2016 | 15 | 0.500 |
Why?
|
| Marketing | 1 | 2016 | 44 | 0.500 |
Why?
|
| Magnetic Resonance Imaging, Cine | 2 | 2025 | 43 | 0.480 |
Why?
|
| Tetralogy of Fallot | 1 | 2014 | 5 | 0.450 |
Why?
|
| Pulmonary Valve Insufficiency | 1 | 2014 | 8 | 0.450 |
Why?
|
| Walking | 1 | 2015 | 85 | 0.450 |
Why?
|
| Death, Sudden, Cardiac | 4 | 2018 | 31 | 0.450 |
Why?
|
| Sex Factors | 8 | 2019 | 1008 | 0.430 |
Why?
|
| Cardiac Surgical Procedures | 1 | 2014 | 54 | 0.430 |
Why?
|
| Diabetes Mellitus | 4 | 2022 | 532 | 0.420 |
Why?
|
| Predictive Value of Tests | 5 | 2019 | 438 | 0.410 |
Why?
|
| Emotions | 1 | 2016 | 251 | 0.410 |
Why?
|
| Recovery of Function | 3 | 2024 | 107 | 0.400 |
Why?
|
| Adult | 17 | 2025 | 13458 | 0.400 |
Why?
|
| Aged, 80 and over | 7 | 2024 | 2803 | 0.390 |
Why?
|
| Prosthesis Failure | 2 | 2024 | 18 | 0.390 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 4 | 2020 | 78 | 0.380 |
Why?
|
| Proportional Hazards Models | 7 | 2025 | 512 | 0.330 |
Why?
|
| Atrial Fibrillation | 3 | 2021 | 121 | 0.330 |
Why?
|
| Anticoagulants | 2 | 2023 | 121 | 0.330 |
Why?
|
| Echocardiography, Transesophageal | 2 | 2021 | 23 | 0.330 |
Why?
|
| Echocardiography | 6 | 2021 | 167 | 0.320 |
Why?
|
| Heart | 2 | 2023 | 181 | 0.310 |
Why?
|
| Prognosis | 7 | 2021 | 850 | 0.310 |
Why?
|
| Diabetic Angiopathies | 2 | 2019 | 26 | 0.300 |
Why?
|
| Retrospective Studies | 7 | 2024 | 2485 | 0.280 |
Why?
|
| Prevalence | 7 | 2025 | 1597 | 0.280 |
Why?
|
| Acute Coronary Syndrome | 2 | 2025 | 43 | 0.270 |
Why?
|
| Hypertrophy, Left Ventricular | 2 | 2025 | 45 | 0.260 |
Why?
|
| Hypoglycemic Agents | 2 | 2019 | 181 | 0.250 |
Why?
|
| Cohort Studies | 5 | 2023 | 1729 | 0.250 |
Why?
|
| Cause of Death | 4 | 2019 | 183 | 0.250 |
Why?
|
| Myocardial Ischemia | 2 | 2025 | 82 | 0.250 |
Why?
|
| Mortality | 2 | 2019 | 174 | 0.250 |
Why?
|
| Practice Guidelines as Topic | 2 | 2025 | 225 | 0.250 |
Why?
|
| Receptors, Tumor Necrosis Factor, Type I | 1 | 2025 | 22 | 0.240 |
Why?
|
| Myocardial Reperfusion Injury | 1 | 2025 | 51 | 0.230 |
Why?
|
| Health Status | 2 | 2019 | 432 | 0.230 |
Why?
|
| Heart Valve Diseases | 1 | 2024 | 15 | 0.230 |
Why?
|
| Developing Countries | 1 | 2025 | 112 | 0.220 |
Why?
|
| Adrenergic beta-Antagonists | 3 | 2019 | 54 | 0.220 |
Why?
|
| Young Adult | 4 | 2019 | 4936 | 0.210 |
Why?
|
| Cerebrovascular Disorders | 1 | 2024 | 43 | 0.210 |
Why?
|
| Heart Ventricles | 1 | 2025 | 123 | 0.210 |
Why?
|
| Age Factors | 5 | 2019 | 1139 | 0.210 |
Why?
|
| Cross-Sectional Studies | 5 | 2025 | 3077 | 0.210 |
Why?
|
| RNA | 1 | 2025 | 266 | 0.200 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2025 | 379 | 0.200 |
Why?
|
| Hemorrhage | 1 | 2023 | 55 | 0.200 |
Why?
|
| Attitude of Health Personnel | 1 | 2025 | 222 | 0.200 |
Why?
|
| Phenotype | 3 | 2022 | 774 | 0.200 |
Why?
|
| Inflammation | 3 | 2023 | 729 | 0.190 |
Why?
|
| Warfarin | 1 | 2023 | 66 | 0.190 |
Why?
|
| Administration, Oral | 1 | 2023 | 256 | 0.190 |
Why?
|
| Kidney Transplantation | 1 | 2023 | 102 | 0.190 |
Why?
|
| Blood Pressure | 1 | 2025 | 662 | 0.180 |
Why?
|
| Surgical Instruments | 1 | 2021 | 7 | 0.170 |
Why?
|
| Hair Follicle | 1 | 2020 | 10 | 0.170 |
Why?
|
| Salvia | 1 | 2020 | 10 | 0.170 |
Why?
|
| Patient Readmission | 2 | 2022 | 120 | 0.170 |
Why?
|
| Europe | 3 | 2025 | 114 | 0.170 |
Why?
|
| Reoperation | 1 | 2020 | 31 | 0.160 |
Why?
|
| Hypertension | 2 | 2025 | 823 | 0.160 |
Why?
|
| Feasibility Studies | 1 | 2021 | 238 | 0.160 |
Why?
|
| Scleroderma, Systemic | 1 | 2019 | 12 | 0.160 |
Why?
|
| Lung Diseases, Interstitial | 1 | 2019 | 13 | 0.160 |
Why?
|
| Fractional Flow Reserve, Myocardial | 2 | 2018 | 21 | 0.160 |
Why?
|
| Sulfur Dioxide | 1 | 2019 | 9 | 0.150 |
Why?
|
| Nitrogen Dioxide | 1 | 2019 | 17 | 0.150 |
Why?
|
| Microvessels | 1 | 2019 | 31 | 0.150 |
Why?
|
| Comorbidity | 5 | 2019 | 725 | 0.150 |
Why?
|
| Ozone | 1 | 2019 | 26 | 0.150 |
Why?
|
| Sulfonylurea Compounds | 1 | 2019 | 17 | 0.150 |
Why?
|
| Carbon Monoxide | 1 | 2019 | 48 | 0.150 |
Why?
|
| Hypertension, Pulmonary | 1 | 2019 | 78 | 0.150 |
Why?
|
| Oxygen Consumption | 2 | 2018 | 111 | 0.140 |
Why?
|
| Heart Diseases | 1 | 2019 | 110 | 0.140 |
Why?
|
| Heart Rate | 2 | 2018 | 261 | 0.140 |
Why?
|
| Cost of Illness | 1 | 2018 | 95 | 0.140 |
Why?
|
| Sphingolipids | 1 | 2018 | 14 | 0.140 |
Why?
|
| Air Pollution | 1 | 2019 | 87 | 0.140 |
Why?
|
| Cardiovascular Physiological Phenomena | 1 | 2018 | 11 | 0.140 |
Why?
|
| Metformin | 1 | 2019 | 74 | 0.140 |
Why?
|
| Guideline Adherence | 1 | 2018 | 98 | 0.140 |
Why?
|
| Linear Models | 2 | 2016 | 311 | 0.140 |
Why?
|
| Anemia | 1 | 2018 | 52 | 0.140 |
Why?
|
| Societies, Medical | 1 | 2018 | 74 | 0.140 |
Why?
|
| Sleep | 1 | 2019 | 179 | 0.140 |
Why?
|
| Interleukin-1 | 1 | 2017 | 39 | 0.140 |
Why?
|
| Republic of Korea | 1 | 2017 | 133 | 0.140 |
Why?
|
| Survival Rate | 4 | 2021 | 353 | 0.140 |
Why?
|
| Coronary Artery Bypass | 1 | 2017 | 47 | 0.140 |
Why?
|
| Plant Extracts | 1 | 2020 | 303 | 0.130 |
Why?
|
| Genome-Wide Association Study | 1 | 2019 | 421 | 0.130 |
Why?
|
| Defibrillators, Implantable | 1 | 2017 | 39 | 0.130 |
Why?
|
| Primary Prevention | 1 | 2017 | 63 | 0.130 |
Why?
|
| Insulin | 1 | 2019 | 255 | 0.130 |
Why?
|
| Public Health | 2 | 2018 | 405 | 0.130 |
Why?
|
| Obesity | 3 | 2019 | 1131 | 0.130 |
Why?
|
| Heart Conduction System | 1 | 2016 | 15 | 0.120 |
Why?
|
| Complementary Therapies | 1 | 2016 | 51 | 0.120 |
Why?
|
| Odds Ratio | 1 | 2017 | 587 | 0.120 |
Why?
|
| Infant, Newborn | 1 | 2019 | 960 | 0.120 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2019 | 727 | 0.120 |
Why?
|
| Adolescent | 2 | 2019 | 5950 | 0.120 |
Why?
|
| Atherosclerosis | 1 | 2017 | 164 | 0.120 |
Why?
|
| Infant | 1 | 2019 | 1143 | 0.120 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2016 | 246 | 0.110 |
Why?
|
| Child, Preschool | 1 | 2019 | 1516 | 0.110 |
Why?
|
| Models, Theoretical | 1 | 2016 | 230 | 0.110 |
Why?
|
| Ventricular Function, Right | 1 | 2014 | 33 | 0.110 |
Why?
|
| Aging | 1 | 2019 | 764 | 0.110 |
Why?
|
| Sex Characteristics | 1 | 2016 | 253 | 0.110 |
Why?
|
| Animals | 5 | 2025 | 16695 | 0.100 |
Why?
|
| United States | 3 | 2018 | 5072 | 0.100 |
Why?
|
| Body Mass Index | 3 | 2023 | 916 | 0.090 |
Why?
|
| Reproducibility of Results | 1 | 2015 | 1058 | 0.090 |
Why?
|
| Influenza A Virus, H1N1 Subtype | 1 | 2011 | 22 | 0.090 |
Why?
|
| Child | 1 | 2019 | 3381 | 0.090 |
Why?
|
| Influenza, Human | 1 | 2011 | 90 | 0.080 |
Why?
|
| Population Surveillance | 1 | 2011 | 245 | 0.080 |
Why?
|
| Severity of Illness Index | 3 | 2018 | 708 | 0.080 |
Why?
|
| Health Status Disparities | 1 | 2016 | 705 | 0.080 |
Why?
|
| Follow-Up Studies | 2 | 2025 | 1051 | 0.080 |
Why?
|
| Asia, Southeastern | 2 | 2019 | 12 | 0.070 |
Why?
|
| Incidence | 3 | 2018 | 1054 | 0.070 |
Why?
|
| Case-Control Studies | 2 | 2025 | 1266 | 0.070 |
Why?
|
| Mice, Inbred C57BL | 2 | 2025 | 1804 | 0.070 |
Why?
|
| Mice | 3 | 2025 | 6490 | 0.070 |
Why?
|
| Delphi Technique | 1 | 2025 | 30 | 0.060 |
Why?
|
| Blood Pressure Monitoring, Ambulatory | 1 | 2025 | 65 | 0.060 |
Why?
|
| Multivariate Analysis | 2 | 2017 | 638 | 0.060 |
Why?
|
| Longitudinal Studies | 2 | 2019 | 1020 | 0.060 |
Why?
|
| Bystander Effect | 1 | 2023 | 15 | 0.050 |
Why?
|
| Myocytes, Cardiac | 1 | 2025 | 173 | 0.050 |
Why?
|
| Thinness | 1 | 2023 | 32 | 0.050 |
Why?
|
| Vaccination | 1 | 2025 | 332 | 0.050 |
Why?
|
| Hong Kong | 1 | 2022 | 29 | 0.050 |
Why?
|
| Signal Transduction | 2 | 2025 | 2111 | 0.050 |
Why?
|
| Testis | 1 | 2023 | 203 | 0.050 |
Why?
|
| Mice, Transgenic | 1 | 2023 | 658 | 0.040 |
Why?
|
| Hair | 1 | 2020 | 38 | 0.040 |
Why?
|
| Lipids | 1 | 2022 | 256 | 0.040 |
Why?
|
| Ventricular Function | 1 | 2019 | 8 | 0.040 |
Why?
|
| Waist-Hip Ratio | 1 | 2019 | 34 | 0.040 |
Why?
|
| Asia, Western | 1 | 2019 | 5 | 0.040 |
Why?
|
| Dipeptidyl-Peptidase IV Inhibitors | 1 | 2019 | 5 | 0.040 |
Why?
|
| Waist Circumference | 1 | 2019 | 90 | 0.040 |
Why?
|
| Telomere | 1 | 2019 | 59 | 0.040 |
Why?
|
| Diuretics | 1 | 2019 | 51 | 0.040 |
Why?
|
| Sweden | 1 | 2018 | 17 | 0.040 |
Why?
|
| Social Class | 1 | 2021 | 286 | 0.040 |
Why?
|
| Internationality | 1 | 2018 | 38 | 0.040 |
Why?
|
| Cross-Over Studies | 1 | 2018 | 112 | 0.040 |
Why?
|
| Evidence-Based Medicine | 1 | 2018 | 107 | 0.040 |
Why?
|
| Cluster Analysis | 1 | 2018 | 206 | 0.040 |
Why?
|
| Adiposity | 1 | 2019 | 155 | 0.040 |
Why?
|
| Seasons | 1 | 2018 | 133 | 0.040 |
Why?
|
| New York | 1 | 2018 | 88 | 0.040 |
Why?
|
| Lipid Metabolism Disorders | 1 | 2017 | 5 | 0.030 |
Why?
|
| Smad3 Protein | 1 | 2017 | 12 | 0.030 |
Why?
|
| Receptors, Interleukin-1 | 1 | 2017 | 10 | 0.030 |
Why?
|
| Geography | 1 | 2018 | 107 | 0.030 |
Why?
|
| Interleukin-18 | 1 | 2017 | 16 | 0.030 |
Why?
|
| Cardiomegaly | 1 | 2018 | 43 | 0.030 |
Why?
|
| France | 1 | 2017 | 21 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2020 | 1112 | 0.030 |
Why?
|
| Morbidity | 1 | 2017 | 97 | 0.030 |
Why?
|
| China | 1 | 2018 | 233 | 0.030 |
Why?
|
| Diabetes Complications | 1 | 2018 | 99 | 0.030 |
Why?
|
| Length of Stay | 1 | 2018 | 231 | 0.030 |
Why?
|
| Canada | 1 | 2017 | 157 | 0.030 |
Why?
|
| India | 1 | 2017 | 105 | 0.030 |
Why?
|
| Cells, Cultured | 1 | 2020 | 1617 | 0.030 |
Why?
|
| Massachusetts | 1 | 2016 | 35 | 0.030 |
Why?
|
| Insulin Resistance | 1 | 2018 | 199 | 0.030 |
Why?
|
| Life Style | 1 | 2018 | 326 | 0.030 |
Why?
|
| Australia | 1 | 2015 | 95 | 0.030 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2017 | 184 | 0.030 |
Why?
|
| Hemodynamics | 1 | 2015 | 101 | 0.030 |
Why?
|
| Educational Status | 1 | 2017 | 335 | 0.030 |
Why?
|
| Cell Proliferation | 1 | 2020 | 1420 | 0.030 |
Why?
|
| Action Potentials | 1 | 2016 | 246 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2016 | 733 | 0.030 |
Why?
|
| Exercise | 1 | 2018 | 674 | 0.020 |
Why?
|
| Sentinel Surveillance | 1 | 2011 | 24 | 0.020 |
Why?
|
| Seroepidemiologic Studies | 1 | 2011 | 71 | 0.020 |
Why?
|
| Bayes Theorem | 1 | 2011 | 121 | 0.020 |
Why?
|
| Health Promotion | 1 | 2017 | 691 | 0.020 |
Why?
|
| Apoptosis | 1 | 2017 | 1541 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2011 | 602 | 0.020 |
Why?
|